We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Low Dose Doxycycline in the Treatment of Corneal Burn

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01886560
Recruitment Status : Unknown
Verified June 2013 by Dan Liang, Sun Yat-sen University.
Recruitment status was:  Not yet recruiting
First Posted : June 26, 2013
Last Update Posted : August 9, 2013
Information provided by (Responsible Party):
Dan Liang, Sun Yat-sen University

Brief Summary:
To evaluate the safety and efficacy of oral low dose doxycycline in the treatment of corneal burn.

Condition or disease Intervention/treatment Phase
Eye Burns Drug: Doxycycline Drug: Placebo Phase 2 Phase 3

Detailed Description:

Severe Ocular Burn often leads to the Ocular surface failure, corneal vascularization dissolved hole or corneal opacity.Because the conventional treatment effect is not ideal, blindness rate is extremely high, has been a very challenging catastrophic ophthalmic emergency.Early effective inhibition of inflammation, promote healing of corneal epithelium is the key of reducing corneal perforation, corneal neovascularization, improving corneal transparency.Existing anti-inflammatory treatment including the hormone and immune inhibitors, auto-serum, non-steroidal anti-inflammatory drugs, amniotic membrane transplantation or amniotic membrane patch, etc.Although these measures have some effect, they have their disadvantages.Select both broad-spectrum anti-inflammatory effects and moderate price, good safety anti-inflammatory drugs is particularly important.

Sub-antimicrobial dose doxycycline posses known anti-inflammatory effects that are separate from their antibacterial mode of action.This mode of action has lead to the routine use of sub-antimicrobial dose doxycycline for treating inflammatory or autoimmune diseases, such as rosacea, periodontitis and multiple sclerosis.We confirmed on the basis of predecessors' studies that low dose oral doxycycline and topical application of doxycycline can accelerate corneal epithelium healing after ocular surface burn, effectively inhibit inflammation mediated corneal new angiogenesis.Its mechanism of action is about downregulate MMP2 and nitric oxide synthase.

Given the previous research obtained the encouraging result, we plan to carry out a clinical research, to explore oral low-dose doxycycline efficacy and safety of the treatment of corneal burns.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prospective, Double-blind, Randomized, Controlled Clinical Trial of Low Dose Doxycycline in the Treatment of Corneal Burn
Study Start Date : September 2013
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns

Arm Intervention/treatment
Placebo Comparator: Placebo
Adding eatable flour into the pills
Drug: Placebo
Tablets placebo one PO per day for 12 weeks
Other Name: dummy

Experimental: Doxycycline treatment
Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks
Drug: Doxycycline
Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
Other Names:
  • Dolotard
  • Tibirox
  • Biomycin

Primary Outcome Measures :
  1. Time for Corneal epithelialization after treatment [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. corneal limbal ischemia [ Time Frame: 12 weeks ]
  2. Safety and tolerability as assessed by adverse events, vital signs [ Time Frame: 24 weeks ]
  3. corneal neovascularization [ Time Frame: 12 weeks ]
  4. Corneal transparency [ Time Frame: 12 weeks ]
  5. cornea ulcer with perforation [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1.age from 18-70 years old, not limited to sex

    2. ocular burn (including chemical injury, thermal burns)

    3. studies of eye with Dua grade (2001) III, within 14 days after burns

    4. about the eye burns

    1. become the research with only one eye
    2. conform to the standards of subjects for the eyes

Choose poor eyesight as in the study

If the vision is the same on both sides, the choice classification is higher as the research of eye

If the binocular vision and graded at the same time, according to a study in can be determined in consultation with the patient's eye

5.signed informed consent form

Exclusion Criteria:

- 1. Only one eye function

2.The exclusion criteria of the eye

A) corneal thinning depth ≥ 1/2CT, corneal perforation or perforation tendency

B, Dua classification I、II、IV、V、VI

C) after injury had received eye operation (such as amniotic membrane transplantation or covering)

D) Poor control of intraocular pressure after anti-glaucoma drug treatment (IOP ≥ 25mmHg)

E) past other corneal diseases

F) past ocular history of radiation therapy or eye operation history

G) eyelid defect, incomplete eyelid closure, entropion, trichiasis

3. Any side formulated after secondary infection

4. Other rule out criteria

A) Tetracycline class history of drug allergy

B) poor control of blood pressure (defined as after treatment with antihypertensive drugs, blood pressure is 150/95mmHg or higher)

C) serious heart, hepatic, renal insufficiency (or myocardial infarction, arrhythmia, myocardial ischemia and cardiac insufficiency, ALT, AST, upper limit of normal or higher by 2.5 times, creatinine upper limit of normal or higher by 1.5 times)

D) during pregnancy or lactation women (defined as pregnancy urine pregnancy test results in this test)

E) child-bearing age subjects (male and female) is suitable precautions during the entire study

F) into the group participated in other clinical subjects before 3 months

G) people with TB

H) nerve with mental illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01886560

Layout table for location contacts
Contact: Dan Liang, MD 0086-20-87331766 liangd2@mail.sysu.edu.cn
Contact: Jingwen Huang 0086-20-87331541 shoouzhang35@sina.com

Layout table for location information
China, Guangdong
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China, 510060
Contact: Dan Liang, MD    0086-20-87331766    liangd2@mail.sysu.edu.cn   
Sponsors and Collaborators
Sun Yat-sen University
Layout table for investigator information
Study Chair: Dan Liang, MD Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
Layout table for additonal information
Responsible Party: Dan Liang, Zhongshan Ophthalmic Center, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT01886560    
Other Study ID Numbers: SunYat-senU2
First Posted: June 26, 2013    Key Record Dates
Last Update Posted: August 9, 2013
Last Verified: June 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Eye Burns
Wounds and Injuries
Eye Injuries
Facial Injuries
Craniocerebral Trauma
Trauma, Nervous System
Nervous System Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents